Insulin glargine + 75% insulin lispro protamine suspension and 25 % insulin lispro injection
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Jul 1, 2001 → Dec 1, 2002
NCT ID
NCT01336751About Insulin glargine + 75% insulin lispro protamine suspension and 25 % insulin lispro injection
Insulin glargine + 75% insulin lispro protamine suspension and 25 % insulin lispro injection is a phase 3 stage product being developed by Sanofi for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT01336751. Target conditions include Diabetes Mellitus, Type 2.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 2 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01336751 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2